Fractyl Health
Edit

Fractyl Health

http://www.fractyl.com/
Last activity: 31.01.2025
Active
Categories: CauseFinTechHardwareHealthTechHumanITManagementMedTechResearchTools
Fractyl Health is a leader in creating innovative therapies to address the root cause of type 2 diabetes.

We were founded based on groundbreaking research and biological insights showing the key role of the intestine in metabolic control. Our therapies are uniquely designed to target and control this controller for the treatment of metabolic disease.

Our lead program, Revita DMR, is a first-in-class procedural therapy that is now in late-stage clinical trials for the treatment of type 2 diabetes.

Our team is made up of passionate innovators at the intersection of biology and technology, working to deliver better real-world outcomes for people with metabolic disease.

Fractyl is located in Lexington, Mass.
Likes
130
Followers
592
Followers
4.51K
Mentions
38
Location: United States, Massachusetts, Lexington
Employees: 51-200
Phone: +1 781-902-8800
Total raised: $251M
Founded date: 2010

Investors 6

Funding Rounds 4

DateSeriesAmountInvestors
02.02.2024IPO$110M-
30.11.2017Series D$44M-
19.11.2015Series C$57M-
04.09.2014Series C$40M-

Mentions in press and media 38

DateTitleDescription
31.01.2025Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Stu...Prioritizing Revita’s clinical development on weight maintenance post-GLP-1 withdrawal in response to significant patient and physician demand in ongoing REMAIN-1 pivotal study; anticipate midpoint data analysis in Q2 2025 and full pivotal ...
12.03.2024UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semagl...Data provides first demonstration of glucose lowering and weight loss potency from pancreas-produced native human GLP-1, highlighting the capacity of pancreatic GLP-1 to provide metabolic control. The human GLP-1 transgene sequence used in ...
12.03.2024UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semagl...-
12.03.2024Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in t...-
02.02.2024Metabolic Disorder-Focused Fractyl Health ‘GUTS’ Out a $110 Million IPOFractyl Health contends its metabolic disorder product candidates could offer long-lasting effects not achievable with in-demand weight loss medications, such as Wegovy and Zepbound. It now has $110 million in IPO cash to help build that ca...
17.06.2021Fractyl Health collects $100M Series FFractyl Health has raised $100 million in a round co-led by Maverick Capital, M28 Capital and Population Health Partners. Based in the Boston area, the company is a developer of therapeutics for metabolic diseases. It plans to use the funds...
16.06.2021In private equity, compensation lags for women in senior positionsThis is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. In general, 2020 proved to be a good year for private equity dealmakers. Even as deal value and v...
16.06.2021In private equity, compensation lags for women in senior positionsThis is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content 4 ways CEOs can build a successful cloud strategy From PwC In general, 2020 proved t...
16.06.2021Fractyl Announces Closing of $100 Million Series F Financing to Expand Clinical Development Programs in Type 2 DiabetesFractyl Health, a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced the closing of a $100 million Series F financing. The financing was led by ne...
10.08.2020Weekly Refresh: Fractyl Raised $55M, Wayfair’s Profitable Q2, and MorePhoto: Shutterstock Indigo Ag raised $360M. The startup combines natural microbiology with tech to make the farming industry more environmentally sustainable. This additional funding brought the total of its Series F raise to $535 million. ...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In